Establishment of Ovarian Cancer Stem Cell Signature

Tech Id: ors000595-1



Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States. Despite similarities in initial disease presentation, the existence of molecular subtypes of ovarian cancer shown in clinical outcomes display a broad range of survival end points. Dr. Orsulic and colleagues have identified a 10-gene biomarker panel providing an opportunity to develop a prognostic/diagnostic test, or utilize the molecular subtype classifications of ovarian cancers in treatment.


Technology Description 

Dr. Orsulic and colleagues at Cedars-Sinai Medical Center have identified a 10-gene biomarker panel that may identify the aggressiveness of a patient's ovarian cancer, resulting in novel therapeutic strategies tailored to patients with the poorest survival outcomes. The data, based on the analysis of nearly 800 ovarian cancer patients, suggests that patients who have elevated levels of genes associated with the biomarker panel have a more aggressive form of disease and a shorter survival. 

The 10-gene signature is robust in its ability to predict poor survival, demonstrated in two large validation datasets consisting of 260 ovarian cancer patient samples and 1,058 pooled ovarian cancer patient samples. These findings indicate that even though patients present with the same disease stage at diagnosis, their survival outcomes differ. The gene signature could be utilized to develop clinical applications, such as personalized treatment strategies focused on molecular subtypes of ovarian cancer.



• Personalized medicine is becoming increasingly common in treating certain types of cancer, but is not yet the norm for ovarian cancer patients. With some patients developing a chronic-type disease that can be maintained on chemotherapy while others are resistant to chemotherapy, strategic approaches customized for treating these different patient groups are desperately needed.

• Currently no prognostic tool exists that distinguishes among these patient groups, and consequently there is a critical need for:

1. prognostic and/or diagnostic classifiers that can reliably distinguish among molecular subtypes of gynecological cancer such as ovarian cancer; and

2. novel treatment therapies accounting for these differences in molecular subtypes.



The finding can be developed into a diagnostic/prognostic test to predict survival outcomes in ovarian cancer patients.


Intellectual Property

PCT/US2013/065537 nationalized into US, Canada, Israel and Australia.

EU patent 2908913 granted



• Cheon et al. A Collagen-Remodeling Gene Signature Regulated by TGF-β Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer. Clin Cancer Res. 2013, 20(3): 711-23. [LINK]

• News article: Ovarian cancer discovery deepens knowledge of survival outcomes ScienceDaily. 2013. [LINK]


Patent Information:
For Information, Contact:
Wenyue Du
Senior Associate - IP Management & Licensing
Sandra Orsulic
Dong_joo (ellen) Cheon
Beth Karlan
Mourad Taghiouart
Xiaojiang Cui
Zhenqiu Liu